

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

October 29, 2021

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051. BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE Scrip code: 532983

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter and half year ended September 30, 2021

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and half year ended September 30, 2021 which were approved by the Board of Directors of the Company, at its meeting held on October 29, 2021 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:20 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar

Head – Legal & Company Secretary

Encl: as above

Phisamercar



BSR&Co.LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Limited review report on unaudited quarterly and year-to-date financial results of RPG Life Sciences Limited under Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To the Board of Directors of RPG Life Sciences Limited

- 1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 ('the Statement').
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

HIMANSHU LALITKUMAR CHAPSEY Digitally signed by HIMANSHU LALITKUMAR CHAPSEY Date: 2021.10.29 16:11:18

Himanshu Chapsey
Partner

Membership No: 105731 UDIN: 21105731AAAAGK9712

Place: Mumbai Date: 29 October 2021



Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375

Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2021

							Rs. in Lakhs)
		Quarter ended			Six months ended		Year ended
	Particulars	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	11,265	10,813	9,713	22,078	18,878	38,914
2	Other Income	71	41	4	112	49	91
3	Total Income (1+2)	11,336	10,854	9,717	22,190	18,927	39,005
4	Expenses						
	(a) Cost of Materials Consumed	1,899	2,087	2,680	3,986	4,594	8,575
	 (b) Purchases of Stock-in-Trade (c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in- 	2,217	1,484	809	3,701	2,314	5,036
	Trade	(673)	(76)	(392)	(749)	(884)	(501)
	(d) Employee Benefits Expense	2,577	2,360	2,441	4,937	4,749	9,466
	(e) Finance Costs(f) Depreciation and Amortisation	17	13	23	30	54	79
	Expense	399	396	420	795	836	1,647
	(g) Other Expenses	2,665	2,663	2,263	5,328	4,508	9,345
	Total Expenses	9,101	8,927	8,244	18,028	16,171	33,647
5	Profit before tax (3-4)	2,235	1,927	1,473	4,162	2,756	5,358
6	Income tax expenses a. Current Tax b. Deferred Tax	670 (10)	578 (9)	473 (115)	1,248 (19)	884 (149)	1,715 (357)
7	Profit for the period (5-6)	1,575	1,358	1,115	2,933	2,021	4,000
8	Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to Profit or Loss	(4)	(4)	(6)	(8)	(12)	(16)
	Other Committee Income Nation To	1	1	1	2	3	4
	Other Comprehensive Income Net of Tax	(3)	(3)	(5)	(6)	(9)	(12)
9	Total Comprehensive Income for the period (7+8)	1,572	1,355	1,110	2,927	2,012	3,988
10	Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11	Other Equity						20,322
12	Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
	(a) Basic (in Rs.)	9.52	8.21	6.74	17.74	12.22	24.19
	(b) Diluted (in Rs.)	9.52	8.21	6.74	17.74	12.22	24.19





Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Notes:

- 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 29, 2021.
- 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.

For RPG Life Sciences Limited

SCIENCE OF MUMBAI OF 400 030.

Yugal Sikri Managing Director Mumbai, October 29, 2021



Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Fax: +91-22-24970127 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Unaudited Balance Sheet as at September 30, 2021

(Rs. in Lakhs)

Particulars	As at September 30, 2021	As at March 31, 2021	
	(Unaudited)	(Audited)	
ASSETS			
Non-current assets			
Property, plant and equipment	7,508	7,850	
Capital work-in-progress	1,376	944	
Other intangible assets	3,248	3,480	
Intangible assets under development	218	233	
Financial assets			
i. Loans	17	18	
ii. Other financial assets	31	28	
Deferred tax assets (Net)	-	6	
Current Tax asset (Net)	123	123	
Other non-current assets	185	72	
Total non-current assets	12,706	12,754	
<u>Current assets</u>			
Inventories	6,722	5,833	
Financial assets			
i. Investments	4,053	-	
ii. Trade receivables	5,474	5,742	
iii. Cash and cash equivalents	1,985	4,036	
iv. Bank balances other than (iii) above	39	39	
v. Other financial assets	108	114	
Other current assets	1,642	1,821	
Total current assets	20,023	17,585	
Total assets	32,729	30,339	







Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Particulars	As at September 30, 2021 (Unaudited)	As at March 31, 2021
EQUITY AND LIABILITIES	(Onaudited)	(Audited)
Equity		
Equity share capital	1,323	1,323
Other equity	22,058	20,322
Total equity	23,381	21,645
LIABILITIES		
Non-current liabilities		
Financial liabilities		
i. Borrowings	4	9
ii. Lease liabilities	47	65
iii. Other financial liabilities	338	338
Provisions	313	313
Deferred tax liabilities (Net)	200	-
Total non-current liabilities	902	725
<u>Current liabilities</u>		
Financial liabilities		
i. Borrowings	11	63
ii. Lease liabilities	47	65
iii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	112	133
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	4,994	4,611
iv. Other financial liabilities	851	1,092
Provisions	1,379	1,361
Current tax liabilities (Net)	297	-
Other current liabilities	755	644
Total current liabilities	8,446	7,969
Total liabilities	9,348	8,694
Total equity and liabilities	32,729	30,339

Note: Previous period figures have been re-grouped / re-classified wherever necessary, to confirm to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.





Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127

Fax: +91-22-24970127 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

Unaudited statement of cash flows for the six months ended September 30, 2021

(Rs. in Lakhs)

			(Rs. in Lakhs)	
		For the period ended	For the period ended	
	Particulars	September 30, 2021	September 30, 2020	
		Unaudited	Unaudited	
Α	Cash Flow from operating activities			
_	Profit before income tax	4,162	2,756	
	Adjustments for	4,102	2,750	
	,			
	Add:	705	926	
	Depreciation and amortisation expenses	795	836	
	Finance costs	30	54	
	Loss on disposal of property, plant and equipment	-	(1)	
	Unrealised exchange rate difference	(47)	(41)	
	Provision for Doubtful Debts and Advances (Net)	8	10	
	Interest received	(30)	(8)	
	Gain on sale of investments	(8)	-	
	Net fair value gain on financial assets mandatorily measured at fair			
	value through profit or loss	(53)	-	
	- '	4,857	3,606	
	Madine social edicates sets	,	,,,,,,	
	Working capital adjustments:	200	(4.00)	
	Decrease/(Increase) in trade receivables	309	(188)	
	(Increase)/Decrease in financial assets - Loans	(2)	1	
	Decrease in other non-current assets	6	6	
	Decrease/(Increase) in other financial assets	6	(7)	
	Decrease/(Increase) in other current assets	179	(383)	
	(Increase) in inventories	(889)	(1,405)	
	Increase in trade payables	362	390	
	(Decrease) in other financial liabilities	(313)	(244)	
	Increase in provisions	10	101	
	Increase in other current liabilities	111	43	
	Cash generated from operations	4,636	1,920	
	Income taxes paid	(727)	(260)	
	Net cash inflow from operating activities	3,909	1,660	
_		,	,	
В	Cash flow from investing activities:	(505)	(424)	
	Acquisition of property, plant and equipment and Intangible assets	(695)	(434)	
	Proceeds from sale of property, plant and equipment and Intangible			
	assets	-	1	
	Movement in Other bank balances (Net)		(196)	
	Investment in Mutual Funds	(4,000)	-	
	Interest received	30	8	
	Net gain on sale of investments	8	<u> </u>	
	Net cash (outflow) from investing activities	(4,657)	(621)	
С	Cash flow from financing activities			
	Repayment of long term borrowings	(6)	(436)	
	Repayment from Short-term Borrowings	(52)	(454)	
	Interest paid	(10)	(31)	
	Repayment of principal portion of lease liability	(35)	(31)	
	Interest paid on lease liability	(9)	(12)	
	Dividend paid	(1,191)	-	
	Net cash (outflow) from financing activities	(1,303)	(964)	
		-	(504)	
	Net (decrease)/increase in cash and cash equivalents	(2,051)	75	
	Add: Cash and cash equivalents at the beginning of the financial period	4,036	54	
	Cash and cash equivalents at the end of the period	1,985	129	